An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine

Study Identifier
UBR-MD-04
CT.gov Identifier
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact
Study Complete

Results Available

Protocol
Available Language(s): English
Statistical Analysis Plan
Available Language(s): English

Study Details

Medical Condition
  • Migraine - General
  • Study Drug
  • Ubrogepant
  • Placebo-matching Ubrogepant
  • Usual Care
  • Phase
    Phase 3
    Sex
    Female & Male
    Age
    18 - 76 Years

    Protocol Summary

    This study will evaluate the long-term safety and tolerability of intermittent treatment with ubrogepant for the acute treatment of migraine over 1 year.

    Study Locations

    Location
    Status
    Location
    Radiant Research, Inc.
    Birmingham, Alabama, United States, 35211
    Status
    Not applicable
    Location
    East Family Physicians PC/Radiant Research, Inc.
    Chandler, Arizona, United States, 85224
    Status
    Not applicable
    Location
    Desert Clinical Research /Radiant Research, Inc.
    Mesa, Arizona, United States, 85213
    Status
    Not applicable
    Location
    Xenoscience, Inc.
    Phoenix, Arizona, United States, 85004
    Status
    Not applicable
    Location
    Central Phoenix Medical Clinic
    Phoenix, Arizona, United States, 85020
    Status
    Not applicable
    Location
    Radiant Research Inc.
    Tucson, Arizona, United States, 85712
    Status
    Not applicable
    Showing {first} - {last} of {total} Results